title: The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin.
authors.affiliation: Servicio de Inmunocomprometidos, Hospital General de Agudos José María Ramos Mejía, Buenos Aires, Argentina. mlosso@hivramos.org.ar
authors.forename: Marcelo H
authors.initials: MH
authors.lastname: Losso
authors.forename: Leonardo D
authors.initials: LD
authors.lastname: Lourtau
authors.forename: Javier J
authors.initials: JJ
authors.lastname: Toibaro
authors.forename: César
authors.initials: C
authors.lastname: Saenz
authors.forename: Claudio
authors.initials: C
authors.lastname: González
mesh_terms: D000328:Adult; D018791:CD4 Lymphocyte Count; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D015497:HIV-1 / Q000502:physiology; D006801:Humans; D008297:Male; D012367:RNA, Viral / Q000097:blood; D012293:Rifampin / Q000008:administration & dosage* / Q000627:therapeutic use; D019438:Ritonavir / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D019258:Saquinavir / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014376:Tuberculosis / Q000150:complications* / Q000188:drug therapy
chemical_list: D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D019258:Saquinavir; D019438:Ritonavir; D012293:Rifampin